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Background: Right ventricular dysfunction (RVD) due to high pulmonary vascular resistance (PVRI) is a significant complication after orthotopic 
heart transplantation (OHT). Limited adult studies have shown improved outcomes with sildenafil. We present our experience with sildenafil for RVD 
following pediatric OHT.
Methods: 13 patients (median age=6.4 yrs, range=0.1-16.8) with RVD and high PVRI on echocardiogram and/or right heart catheterization 
(RHC) after OHT received sildenafil. Three patients had sildenafil stopped due to hypoxia. Of the remaining 10 patients, 8 had RHC before and after 
institution of sildenafil (mean follow-up RHC=16 +/- 4 days). Patients were initially treated with intravenous (IV) and inhaled vasodilators as needed. 
Sildenafil dosage range was 0.5-1.5 mg/kg/dose TID.
Results: IV or inhaled vasodilators were weaned using sildenafil in all 10 patients. Sildenafil significantly decreased the systolic pulmonary artery 
pressure (41.3 +/- 9.6 vs. 32.5 +/- 9.2 mm Hg, p=0.047), transpulmonary gradient (14.0 +/- 5.1 vs. 9.6 +/- 3.7 mm Hg, p=0.030) and PVRI (4.6 
+/- 1.4 vs. 3.0 +/- 1.2 Woods units/m2, p=0.005). Right ventricular function improved in all 10 patients. In-hospital survival was 92.3% with no 
deaths from RVD. Six patients have been successfully weaned off sildenafil thus far (median length of treatment=114 days, range=77-255).
Conclusion: In addition to IV and inhaled vasodilators, sildenafil can be used to successfully treat acute RVD and high PVRI after pediatric OHT. 
